Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

Flatt PR, Bailey CJ, Green BD.

Curr Drug Metab. 2009 Feb;10(2):125-37. Review.

PMID:
19275548
2.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
3.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
4.

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

Langley AK, Suffoletta TJ, Jennings HR.

Pharmacotherapy. 2007 Aug;27(8):1163-80. Review.

PMID:
17655515
5.

Therapies for the treatment of type 2 diabetes mellitus based on incretin action.

Gallwitz B.

Minerva Endocrinol. 2006 Jun;31(2):133-47. Review.

PMID:
16682937
6.

Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.

Triplitt C, Wright A, Chiquette E.

Pharmacotherapy. 2006 Mar;26(3):360-74. Review.

PMID:
16503716
7.
8.

[The incretin effect: a new therapeutic target in type 2 diabetes].

Féry F.

Rev Med Brux. 2007 Sep;28(4):329-35. French.

PMID:
17958029
9.
10.

New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.

Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G.

Expert Opin Pharmacother. 2008 Jun;9(9):1495-507. doi: 10.1517/14656566.9.9.1495 . Review.

PMID:
18518780
11.

Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C.

Diabetes Metab. 2005 Jun;31(3 Pt 1):233-42. Review.

PMID:
16142014
12.

Biology of incretins: GLP-1 and GIP.

Baggio LL, Drucker DJ.

Gastroenterology. 2007 May;132(6):2131-57. Review.

PMID:
17498508
13.

Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes.

Havale SH, Pal M.

Bioorg Med Chem. 2009 Mar 1;17(5):1783-802. doi: 10.1016/j.bmc.2009.01.061. Epub 2009 Jan 31. Review.

PMID:
19217790
14.
15.

Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.

Campbell RK.

Ann Pharmacother. 2007 Jan;41(1):51-60. Epub 2006 Dec 26. Review.

PMID:
17190843
16.

DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes.

Deacon CF, Carr RD, Holst JJ.

Front Biosci. 2008 Jan 1;13:1780-94. Review.

PMID:
17981667
17.

DPP4 inhibitors: a new approach in diabetes treatment.

Doupis J, Veves A.

Adv Ther. 2008 Jul;25(7):627-43. doi: 10.1007/s12325-008-0076-1. Review.

PMID:
18641927
18.

Incretin-based therapies: mimetics versus protease inhibitors.

Brubaker PL.

Trends Endocrinol Metab. 2007 Aug;18(6):240-5. Epub 2007 Jul 12. Review.

PMID:
17629492
19.

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. Review.

PMID:
18054732
20.

Dipeptidyl peptidase IV inhibitors and diabetes therapy.

McIntosh CH.

Front Biosci. 2008 Jan 1;13:1753-73. Review.

PMID:
17981665

Supplemental Content

Support Center